Drug Trial Radar · NCT06285643
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
59
Actual
Start
Jun 11, 2024
Primary completion
Aug 31, 2028
Study completion Aug 31, 2028
Sponsor
- Lead sponsor
- AskBio IncIndustry
- Sponsor type
- Industry
- Collaborators
- Bayer
- First posted
- Feb 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
Conditions
- Parkinson Disease
Interventions
AAV2-GDNF gene therapyDrug
Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
control surgeryProcedure
Bilateral partial burr/twist holes without dural penetration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to Month 18 on PD Motor DiaryTime frame: 18 months
Locations
46 sites in 4 countries. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona
UCI Alpha Clinic (Neurology)
Irvine, California
Loma Linda University (Neurology)
Loma Linda, California
Loma Linda University (Surgical)
Loma Linda, California
University of California San Francisco (Neurology)
San Francisco, California
University of San Francisco (Surgical)
San Francisco, California
CenExel Rocky Mountain Clinical Research (Neurology)
Englewood, Colorado
Georgetown University (Neurology)
Washington D.C., District of Columbia
Parkinson's Disease and Movement Disorders Center of Boca Raton (Neurology)
Boca Raton, Florida
University of Florida
Gainesville, Florida
University of Miami
Miami, Florida
Orlando Health Neuroscience Institute
Orlando, Florida
Parkinson's Disease Treatment Center of Southwest Florida (Neurology)
Port Charlotte, Florida
Emory University (Surgical)
Atlanta, Georgia
Rush University Medical Center (Neurology)
Chicago, Illinois
University of Kansas Medical Center (Neurology)
Kansas City, Kansas
Massachusetts General Hospital (Neurology)
Boston, Massachusetts
Massachusetts General Hospital (Surgical)
Boston, Massachusetts
Michigan State University (Neurology)
East Lansing, Michigan
Quest Research Institute (Neurology)
Farmington Hills, Michigan
Cleveland Clinic Lou Ruvo (Neurology)
Las Vegas, Nevada
Columbia University
New York, New York
University of North Carolina (Neurology)
Chapel Hill, North Carolina
Duke Neurosurgery (Surgical)
Durham, North Carolina
Duke University (Neurology)
Durham, North Carolina
Ohio State University (Surgical)
Columbus, Ohio
University of Pennsylvania (Neurology)
Philadelphia, Pennsylvania
Vanderbilt University (Neurology)
Nashville, Tennessee
Texas Movement Disorder Specialists
Georgetown, Texas
Houston Methodist (Neurology)
Houston, Texas
Houston Methodist (Surgical)
Houston, Texas
University of Utah
Salt Lake City, Utah
EvergreenHealth Research Department (Neurology)
Kirkland, Washington
University of Wisconsin (Neurology)
Madison, Wisconsin
Charité - Universitätsmedizin Berlin (Surgical)
Berlin, Germany
Philipps-Universität Marburg (Neurology)
Marburg, Germany
Universitätsklinikum Tübingen (Neurology)
Tübingen, Germany
Universitätsklinikum Tübingen (Surgical)
Tübingen, Germany
Universitätsklinikum Würzburg (Neurology)
Würzburg, Germany
Copernicus Podmiot Leczniczy, Szpital św. Wojciecha (Neurology)
Gdansk, Poland
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.